normal human endometrial epithelial cells heecs Search Results


human endometrial epithelial cells heecs cp- h058  (Procell Inc)
90
Procell Inc human endometrial epithelial cells heecs cp- h058
Human Endometrial Epithelial Cells Heecs Cp H058, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human endometrial epithelial cells heecs cp- h058/product/Procell Inc
Average 90 stars, based on 1 article reviews
human endometrial epithelial cells heecs cp- h058 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human endometrial epithelial cells (heuec)  (Lifeline Cell Technology)
90
Lifeline Cell Technology human endometrial epithelial cells (heuec)
<t>Endometrial</t> cancer cell growth is dependent on CTA TransSigGroup 1 genes. ( A ) Immunoblots showing protein expression of CTAs KIF2C, NUF2, and CEP55 in immortalized human endometrial <t>epithelial</t> cells (iHEuEC) and various endometrial cancer cell lines. Numerical values in each lane indicate fold change in expression of indicated protein relative to its expression in iHEuEC cells. ( B ) Relative growth of HEC-1-B cells after siRNA-mediated knockdown of indicated CTA genes (KIF2C, CEP55 and NUF2) by clonogenic survival assay, quantified relative to control siRNA transfected cells. ( C ) Immunoblots showing protein levels of KIF2C, NUF2 and CEP55 in iHEuEC cells stably expressing Dox-inducible oncogenes CCNE1 , KRAS G12V and c-MYC , relative to WT and iHEuEC empty vector (EV) transformed cells. iHEuEC cells were treated with Doxycycline (Dox) 200 ng/ml for 48h. Numerical values in each lane indicate fold change in expression relative to protein levels in their respective no Dox controls. ( D ) Relative growth of iHEuEC EV and iHEuEC expressing mutant KRAS G12V after transfection with either non-targeting Control (siControl) or siRNA targeting NUF2 (siNUF2). Relative growths were measured with or without Dox treatment (200 ng/ml) by clonogenic survival assay. Quantification of growth is relative to iHEuEC EV siControl cells (-Dox). (B) One-way ANOVA, Dunnett post-test, mean ± SD. (C) Two-way ANOVA, Dunnett post-test, mean ± SD. * P < 0.05, *** P < 0.0005, **** P < 0.00005.
Human Endometrial Epithelial Cells (Heuec), supplied by Lifeline Cell Technology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human endometrial epithelial cells (heuec)/product/Lifeline Cell Technology
Average 90 stars, based on 1 article reviews
human endometrial epithelial cells (heuec) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Endometrial cancer cell growth is dependent on CTA TransSigGroup 1 genes. ( A ) Immunoblots showing protein expression of CTAs KIF2C, NUF2, and CEP55 in immortalized human endometrial epithelial cells (iHEuEC) and various endometrial cancer cell lines. Numerical values in each lane indicate fold change in expression of indicated protein relative to its expression in iHEuEC cells. ( B ) Relative growth of HEC-1-B cells after siRNA-mediated knockdown of indicated CTA genes (KIF2C, CEP55 and NUF2) by clonogenic survival assay, quantified relative to control siRNA transfected cells. ( C ) Immunoblots showing protein levels of KIF2C, NUF2 and CEP55 in iHEuEC cells stably expressing Dox-inducible oncogenes CCNE1 , KRAS G12V and c-MYC , relative to WT and iHEuEC empty vector (EV) transformed cells. iHEuEC cells were treated with Doxycycline (Dox) 200 ng/ml for 48h. Numerical values in each lane indicate fold change in expression relative to protein levels in their respective no Dox controls. ( D ) Relative growth of iHEuEC EV and iHEuEC expressing mutant KRAS G12V after transfection with either non-targeting Control (siControl) or siRNA targeting NUF2 (siNUF2). Relative growths were measured with or without Dox treatment (200 ng/ml) by clonogenic survival assay. Quantification of growth is relative to iHEuEC EV siControl cells (-Dox). (B) One-way ANOVA, Dunnett post-test, mean ± SD. (C) Two-way ANOVA, Dunnett post-test, mean ± SD. * P < 0.05, *** P < 0.0005, **** P < 0.00005.

Journal: NAR Cancer

Article Title: The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities

doi: 10.1093/narcan/zcae015

Figure Lengend Snippet: Endometrial cancer cell growth is dependent on CTA TransSigGroup 1 genes. ( A ) Immunoblots showing protein expression of CTAs KIF2C, NUF2, and CEP55 in immortalized human endometrial epithelial cells (iHEuEC) and various endometrial cancer cell lines. Numerical values in each lane indicate fold change in expression of indicated protein relative to its expression in iHEuEC cells. ( B ) Relative growth of HEC-1-B cells after siRNA-mediated knockdown of indicated CTA genes (KIF2C, CEP55 and NUF2) by clonogenic survival assay, quantified relative to control siRNA transfected cells. ( C ) Immunoblots showing protein levels of KIF2C, NUF2 and CEP55 in iHEuEC cells stably expressing Dox-inducible oncogenes CCNE1 , KRAS G12V and c-MYC , relative to WT and iHEuEC empty vector (EV) transformed cells. iHEuEC cells were treated with Doxycycline (Dox) 200 ng/ml for 48h. Numerical values in each lane indicate fold change in expression relative to protein levels in their respective no Dox controls. ( D ) Relative growth of iHEuEC EV and iHEuEC expressing mutant KRAS G12V after transfection with either non-targeting Control (siControl) or siRNA targeting NUF2 (siNUF2). Relative growths were measured with or without Dox treatment (200 ng/ml) by clonogenic survival assay. Quantification of growth is relative to iHEuEC EV siControl cells (-Dox). (B) One-way ANOVA, Dunnett post-test, mean ± SD. (C) Two-way ANOVA, Dunnett post-test, mean ± SD. * P < 0.05, *** P < 0.0005, **** P < 0.00005.

Article Snippet: Human Endometrial Epithelial Cells (HEuEC) cells were purchased from (Lifeline Cell Technology, #FC-0078) and cultured in DMEM:F12 medium containing 10% FBS, 1% Penicillin-Streptomycin, and 1% Insulin-transferrin-selenium (Gibco, #41400045).

Techniques: Western Blot, Expressing, Knockdown, Clonogenic Cell Survival Assay, Control, Transfection, Stable Transfection, Plasmid Preparation, Transformation Assay, Mutagenesis